K
Kelly Brooks
Researcher at Princess Margaret Cancer Centre
Publications - 5
Citations - 117
Kelly Brooks is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Selumetinib & Malaria. The author has an hindex of 3, co-authored 4 publications receiving 70 citations.
Papers
More filters
Journal ArticleDOI
A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
Grainne M. O'Kane,Shereen Ezzat,Anthony M. Joshua,Isabelle Bourdeau,Raya Leibowitz-Amit,Raya Leibowitz-Amit,Harold J. Olney,Monika K. Krzyzanowska,Dean Reuther,Soo Chin,Lisa Wang,Kelly Brooks,Aaron R. Hansen,Sylvia L. Asa,Jennifer J. Knox +14 more
TL;DR: The overall response rate of sunitinib was low in unselected patients with progressive PCC/PGL, and patients with germline variants in RET or in the subunits of SDH may derive greatest benefit.
Journal ArticleDOI
A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): A study of the Princess Margaret Phase II Consortium
Stephanie Lheureux,Anna V. Tinker,Blaise A. Clarke,Prafull Ghatage,Stephen Welch,Johanne I Weberpals,Neesha C. Dhani,Marcus O. Butler,Katia Tonkin,Qian Tan,David S.P. Tan,Kelly Brooks,Janelle Ramsahai,Lisa Wang,Nhu-An Pham,Patricia Shaw,Ming-Sound Tsao,Swati Garg,Tracy Stockley,Tracy Stockley,Tracy Stockley,Amit M. Oza +21 more
TL;DR: ENMD-2076 was well tolerated with main related grade 3 toxicities being hypertension, proteinuria, and diarrhea, and warrants further investigation as a potential predictive biomarker.
Journal ArticleDOI
Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial
Mark Doherty,Vincent C. Tam,Mairéad G McNamara,David W. Hedley,Neesha C. Dhani,Eric Chen,Raymond Woo-Jun Jang,Patricia A. Tang,Hao-Wen Sim,Grainne M. O'Kane,Stephanie DeLuca,Lisa Wang,Kelly Brooks,Jennifer J. Knox +13 more
TL;DR: Sel (AZD6244, ARR142886) is an oral MEK inhibitor, with preclinical evidence of synergy with Gem in BTC, and CisGem is standard first-line treatment for advanced BTC.
Journal ArticleDOI
Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.
Stephanie Lheureux,Julia V. Burnier,Qian Tan,Yada Kanjanapan,Blaise A. Clarke,Anna V. Tinker,Prafull Ghatage,Neesha C. Dhani,Marcus O. Butler,Stephen Welch,Johanne I Weberpals,David Shao Peng Tan,Kelly Brooks,Janelle Ramsahai,Lisa Wang,Patricia Shaw,Ming-Sound Tsao,Swati Garg,Tracy Stockley,Amit M. Oza +19 more
TL;DR: ENMD-2076 was well tolerated with main related AE: hypertension, nausea, nausea and diarrhea, and was able to tolerate main relatedAEs by IHC, media...
Journal ArticleDOI
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.
Kirsten E. Lyke,Andrea A. Berry,Kaitlin Mason,Azza H. Idris,Mark O'Callahan,Myra Happe,Larisa Strom,Nina M. Berkowitz,M. Guech,Zong-lan Hu,Mike Castro,Manjula Basappa,Lu Wang,Kwang Huei Low,LaSonji A. Holman,Floreliz Mendoza,Ingelise J. Gordon,Sarah H. Plummer,Olga Trofymenko,Kathleen S. Strauss,Sudhaunshu Joshi,Biraj Shrestha,Matthew Adams,Andrezza C. Chagas,Jittawadee Murphy,Judith A Stein,Somia P. Hickman,Andrew McDougal,Bob C. Lin,Sandeep Narpala,Sandra Vazquez,L. R. Serebryannyy,Adrian B. McDermott,Martin R. Gaudinski,Edmund V. Capparelli,Emily E. Coates,Richard L. Wu,Julie E. Ledgerwood,Lesia K. Dropulic,Robert A. Seder,Cheryl A. Young,Colleen Boyce,Jennifer Winkler,Susan Holian,Nancy Greenberg,Shirley George,Alyson Kwon,Brenda Dorsey,Ana Raquel Da Costa,William G. Witt,Daryl Grays,Arren Gapasin,Paula J. Bernal,Jeffrey K. Floyd,Eric Goldstein,Leslie A. Howe,Myo-yong Lee,J.O. Marrón,Kelly Brooks,Lisa Maureen Turek,P. Dwain Farley,Shantel Frels,Delores Booth,Jason G. D. Gall,Kevin Carlton,G. Albright,Nadia Amharref,K.M. Atallah,Sashikanth Banappagari,Niutish Bastani,Daniel Blackstock,Bobby Boonyaratanakornkit,Elizabeth Carey,Adam Charlton,Rajoshi Chaudhuri,Alegria M. Caringal,Mingzhong Chen,Peifeng Chen,Daniel B. Gowetski,Krishana C. Gulla,Eric Hastings,J. Horwitz,Vera B. Ivleva,Dan Kordella,Lisa A. Kueltzo,Sara K Lagler,Mat Jean Le,James Chun-I Lee,P. Lei,Yile Li,Attila Nagy,Aakash Patel,Peyi Runsewe,William R. Shadrick,Shamitha Shetty,Hairong Wang,C. Webber,Farah Vejzagic,Yoo Jung Yang +98 more
TL;DR: CIS43LS was safe and well tolerated, and conferred protection against P falciparum at low doses and by the subcutaneous route, providing evidence that this approach might be useful to prevent malaria across several clinical use cases as mentioned in this paper .